High-risk patients usually include those with cirrhosis
caused by hepatitis B or C, or alcoholic or nonalcoholic steatohepatitis.
The study included 130 patients with liver cirrhosis
Limited information is available about the epidemiology, prevalence and the natural history of the disease as its diagnosis is difficult because of near normal cardiac function at rest and majority are diagnosed during phases of clinical decompensation of cirrhosis
in which they present with features of diastolic heart failure and/or high-output heart failure.
The company said Mavyret is the first treatment of eight weeks duration approved for all HCV genotypes 1-6 in adult patients without cirrhosis
who have not been previously treated.
The POLARIS-1 study has evaluated Vosevi for 12 weeks in adults with hepatitis C virus genotype 1, 2, 3, 4, 5 or 6 with or without compensated cirrhosis
who had failed prior treatment with an NS5A inhibitor-containing regimen.
is known to be associated with "extra-hepatic hemorrhagic and thrombotic processes, such as GI bleeding and venous thromboembolism.
Results: Of 216 patients included, liver cirrhosis
was present in 112 (51.
Patients having liver cirrhosis
only due to chronic hepatitis C virus, portal vein diameter >12mm or spleen size >12cm in long axis and ascites with no previous history of variceal banding were included.
Material and Methods: A Total of 100 consecutive patients of cirrhosis
secondary to viral hepatitis C infection fulfilling the inclusion criterion were taken from wards and emergency department of hospital.
Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cirrhosis
and features dormant and discontinued projects.
Eighty-two patients with cirrhosis
(Child-Pugh classes A, B, and C; mild, moderate, and severe, respectively) were randomly assigned to receive 200 or 400 mcg/day of selenium as selenate, 200 [micro]g/day of selenium as selenomethionine, or placebo for 4 weeks.
Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the use of VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without ribavirin (RBV) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection and compensated cirrhosis
LAT Pharma is developing novel medicines to treat life-threatening complications of liver cirrhosis
According to a study, reported by Radio Pakistan,drinking two additional cups of coffee a day has been linked to a 44% lower risk of developing liver cirrhosis
Researchers who studied data on nearly half a million men and women found that drinking two extra cups of coffee per day is linked to a 44 percent lower risk of developing liver cirrhosis
and a nearly 50 percent lower risk of death from the disease.